American Association for Cancer Research Names Officers and Directors for 1998-1999

Publication
Article
OncologyONCOLOGY Vol 12 No 5
Volume 12
Issue 5

The American Association for Cancer Research (AACR) has named its officers and directors for 1998-1999. Webster K. Cavenee, PhD, will serve as AACR president for 1998-1999 with Daniel D. Von Hoff, MD, assuming the role of President-

The American Association for Cancer Research (AACR) has named its officers and directors for 1998-1999. Webster K. Cavenee, PhD, will serve as AACR president for 1998-1999 with Daniel D. Von Hoff, MD, assuming the role of President-Elect. Donald S. Coffey, PhD is past-president.

Dr. Cavenee is currently director of the Ludwig Institute for Cancer Research (San Diego Branch) and head of its Laboratory of Tumor Biology. He is also a professor in the department of medicine and a member of the Center for Molecular Genetics at the University of California-San Diego, La Jolla, California. He has been an associate editor for three of the AACR’s four journals and has also served on its Board of Directors.

Dr. Von Hoff, the new president-elect, has been an AACR member since 1977 and has an international reputation for his work in clinical trials and drug discovery. The AACR recognized his work last year by awarding him the Richard and Hinda Rosenthal Foundation Award. He is currently director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio. His service to the AACR includes a term on the Board of Directors and nearly 15 years as an associate editor of Cancer Research.

Past-president Dr. Coffey is professor of oncology, pharmacology, and molecular sciences and the Catherine Iola and J. Smith Michael Distinguished Professor of Urology at the Johns Hopkins University School of Medicine. He also serves as director of research laboratories, Department of Urology, at the Johns Hopkins Hospital in Baltimore, Maryland.

The Association also announced the election of Karen S. H. Antman, MD, J. Carl Barrett, PhD, Tom Curran,PhD, and Jean Y. J. Wang, PhD, to the Board of Directors of the Association. They will serve 3-year terms.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content